Should I get this soreness checked now?

Which warning signs can't wait?

Get prompt care for heat, marked swelling and fever. A joint infection can cause harm quickly. Sudden trouble putting weight on the joint also needs care. So does an obvious change in its shape.

Back pain needs special attention with new weakness. Spreading numbness is another warning. Lost bladder or bowel control makes it an emergency. Don't send those problems through a regular clinic form.

New shortness of breath with calf swelling also needs quick care. These signs aren't the time to compare office procedures.

Could an office procedure fit my joint?

Regenerative treatments are the clinic term for procedures using your blood, marrow or fat. The material is prepared in an office and placed near the sore joint. You can discuss one after an exam. Your past care and the joint's wear both matter.

Research gives more information about mildly worn knees than badly worn joints. That doesn't prove the procedure will help you. Severe wear may call for a surgical opinion. Active infection or bleeding trouble can also change what is safe.

You'll need a doctor to review your medicines. A consultation can't promise treatment or relief.

What happens during the visit?

You'll describe where and when it hurts. The person examining you may check motion, strength and swelling. You'll talk about the care you've tried. Bring records if another doctor examined the joint.

Ask for the exact product name in writing. Find out whether it comes from blood, marrow, fat or a donor. Ask about price, healing time and later visits. Ask what happens if relief doesn't come.

You can also ask about exercise, medicine and surgery. Leave only when you understand each reasonable choice.

What risks should I ask about?

Taking marrow from the pelvis can cause bruising, bleeding or infection. Material from a donor contains tissue from another person. Ask how that tissue was checked, stored and kept clean. Your medicines may add bleeding risk too.

Ask who will help if trouble starts after hours. You'll also want written instructions for later care. Find out which changes need a call. Ask where you would go for urgent help.

If the answers aren't clear, don't pay yet. Safety questions belong before any procedure begins.

Sources

1. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

3. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

4. In orders issued 26 December 2024 and announced 8 January 2025, a federal court permanently banned the co-founders of the Stem Cell Institute of America and their companies from marketing any regenerative medicine treatment, and ordered $5,155,146 in refunds and civil penalties. The court found on summary judgment that they published false and misleading advertisements about the efficacy and approval of stem cell injections for osteoarthritis, neuropathy and joint pain; their clinic charged up to $5,000 per injection and the customers were almost exclusively elderly and disabled people.

   US Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. , 2025.

5. 21 CFR 1271.10(a) sets the four criteria a human cell or tissue product must meet to be regulated SOLELY under section 361 of the Public Health Service Act: it must be minimally manipulated; intended for homologous use only, as reflected by labeling and advertising; not combined with another article beyond water, crystalloids or a preserving agent; and either have no systemic effect and not depend on the metabolic activity of living cells, or else be for autologous use, use in a close blood relative, or reproductive use.

   US Code of Federal Regulations, Title 21 — 21 CFR 1271.10 - Are my HCT/P's regulated solely under section 361 of the PHS Act. , 2004.